An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination with DaratUMumab followed by Maintenance with Daratumumab in the Frontline Setting of Primary Plasma CEll LEukemIA: A Trial of the Greek Myeloma Study Group. The "EUMELEIA" Study
Latest Information Update: 17 Oct 2024
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary)
- Indications Plasma cell leukaemia
- Focus Therapeutic Use
- Acronyms The EUMELEIA Study
- 25 Aug 2021 New trial record